Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist.
about
Potential of Glutamate-Based Drug Discovery for Next Generation AntidepressantsHomer1/mGluR5 activity moderates vulnerability to chronic social stressEmerging targets for antidepressant therapiesNovel targets for antidepressant therapiesOlfactory bulbectomy increases food intake and hypothalamic neuropeptide Y in obesity-prone but not obesity-resistant ratsA pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal.On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039.Development of allosteric modulators of GPCRs for treatment of CNS disordersAdvances in the treatment of depressionFuture prospects in depression researchAllosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family.Therapeutic potential of metabotropic glutamate receptor modulators.Loss of Metabotropic Glutamate Receptor 5 Function on Peripheral Benzodiazepine Receptor in Mice Prenatally Exposed to LPS.Novel Glutamatergic Treatments for Severe Mood Disorders.Are compounds acting at metabotropic glutamate receptors the answer to treating depression?Emerging treatments for depression.Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.Emotional Impairment and Persistent Upregulation of mGlu5 Receptor following Morphine Abstinence: Implications of an mGlu5-MOPr Interaction.The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related DisordersCharacterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [¹¹C]ABP688Therapeutic Modulation of Glutamate Receptors in Major Depressive DisorderInvestigational NMDA receptor modulators for depression.Novel glutamatergic drugs for the treatment of mood disorders.Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents.Tyrosine phosphorylation of glutamate receptors by non-receptor tyrosine kinases: roles in depression-like behavior.Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.Glutamate-Based Drug Discovery for Novel Antidepressants.Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.Metabotropic glutamate receptors: potential drug targets for psychiatric disorders.Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression.In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons.Alterations in mGlu5 receptor expression and function in the striatum in a rat depression model.The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent.Association of social defeat stress-induced anhedonia-like symptoms with mGluR1-dependent decrease in membrane-bound AMPA-GluR1 in the mouse ventral midbrain.Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.
P2860
Q26782274-A3B0AC08-209A-47DA-A7EF-6A29AAB04733Q27311111-9F7691D2-8932-437D-87BD-1FC7DBC64AA7Q28247614-749DC3A3-9D80-4D95-9063-58E110F5F128Q28648254-531D717E-AC03-4EFD-9C7F-F0DF9605BEEAQ30494178-6FD4CF1A-FCAD-4944-B91C-EDE1F6921480Q30987882-DB45C983-46E6-40B4-9402-2C4F45BCC5FEQ33566228-731D5DB0-D345-4A43-9CE6-E4FA4CF437CBQ34130874-7A6709D5-C4BA-4A94-969A-3B8BBDC16DE3Q34373958-8C885B42-4334-4866-B812-3B8637A911E9Q34496251-497D485A-1204-4088-A3C7-188B7AFB4970Q35236701-154DA26F-79C3-4F30-BC81-8E3D7C8412B5Q35529175-D8601689-5AA1-46AC-89AC-55B4ED252EBCQ35778704-BB333BE0-858F-440D-9A62-7BE4893A3A21Q35831877-1F431605-B689-426E-9828-56802AC20B30Q36498659-23BE0564-7869-419F-AFAA-A2C1576D788BQ36654331-1530303C-BB4B-4FCA-9DF2-991BF28A9112Q36655168-C2CCE7C8-CF44-44DE-9D0A-833F56B31693Q36899381-7AED99F5-E985-4567-9470-5D09A97CDB67Q37137790-1FD5954C-08BB-4D60-A16D-842EA863B7A1Q37172873-FAACC895-93F0-47C5-9F03-F194C163FCFFQ37347468-865CA5E9-A4DA-49A1-82B0-A1BE22E3D022Q37668014-32293318-E05F-48F9-A925-2008C136056EQ37957965-40D7FAA6-8B04-4A09-B8DA-9EA56F121272Q38131480-C42C5AC2-31B1-406D-9B40-4F7C8F364019Q38310492-8A6EE825-7970-4785-9986-A356EFBFB1AEQ38678531-5E7F7AAD-7673-474A-AB82-D94F4DC2D82DQ38838637-6727003C-42D4-41B8-BA88-7A73DBDC15EFQ38895017-E251E73D-0752-4904-9012-827E62C531A2Q39180685-9AD12266-4805-4F4A-AF75-28262C7428E9Q41157725-F71859FE-E56C-414D-85F2-22B5DA178875Q41994846-DF0B35EE-7F99-4AD6-BB75-4F13F400A27AQ42734765-B3E6D81F-2AAB-41F8-8052-79689F2221EDQ47555397-313F0259-D23D-432E-B38B-05A9C236EFD0Q47745303-EBAEB70B-7BDB-4344-8F67-7985480D106BQ47850446-66E83593-4947-4B86-8B7E-5D5F3327A028Q52600080-4478AF07-A5EA-4739-B947-76D869D51CBF
P2860
Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Potential antidepressant-like ...... y selective mGluR5 antagonist.
@en
type
label
Potential antidepressant-like ...... y selective mGluR5 antagonist.
@en
prefLabel
Potential antidepressant-like ...... y selective mGluR5 antagonist.
@en
P50
P1476
Potential antidepressant-like ...... y selective mGluR5 antagonist.
@en
P2093
Kinga Kłak
P304
P356
10.1016/J.PBB.2005.06.015
P407
P577
2005-08-01T00:00:00Z